Bottlebrush prodrug provides a novel strategy for nanomedicine-mediated combination therapy of multiple myeloma
نویسندگان
چکیده
منابع مشابه
Nanomedicine-Mediated Combination Drug Therapy in Tumor
REVIEW ARTICLE Nanomedicine-Mediated Combination Drug Therapy in Tumor Dazhong Chen, Fangyuan Xie, Duxin Sun, Chuan Yin, Jie Gao and Yanqiang Zhong Department of Pharmaceutical Sciences, Second Military Medical University, 325 Guohe Road, Shanghai 200433, China Department of Gastroenterology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China Department of Pharmaceu...
متن کاملP184: Combination of Herbal Medicine and Nanomedicine: a Novel Therapeutic Target for Neurodegenerative Diseases
Inflammation is a pathologic condition that includes a wide range of diseases namely neurodegenerative diseases. Several natural anti-inflammatory components have been identified in plant extracts used in traditional medicine for the relief of inflammation. Herbal medicine is showing difficulty in crossing the blood-brain barrier (BBB). So that the ability to pass the BBB is the main concern fo...
متن کاملNanomedicine for Combination Therapy of Cancer
a Department of Chemistry, The University of Chicago, Chicago, IL 60637, USA b Department of Radiation and Cellular Oncology, The Ludwig Center for Metastasis Research, The University of Chicago, Chicago, IL 60637, USA c Department of Medicine, The University of Chicago Medical Center, Chicago, IL 60637, USA d Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, The Univers...
متن کاملCombination Therapy for Multiple Myeloma: How Far Have We Come?
Multiple myeloma (MM) is a malignant neoplasm of plasma cells that constitutes 1% of all cancers and 10% of hematologic neoplasms. MM is the second most common hematologic malignancy after nonHodgkin’s lymphoma. It is estimated that 21,700 new cases of MM (approximately 12,190 men and 9,510 women) will be diagnosed during 2012 in the United States, and approximately 10,710 individuals (6,020 me...
متن کاملCarfilzomib boosted combination therapy for relapsed multiple myeloma
Carfilzomib is a proteasome inhibitor that binds selectively and irreversibly to the 20S proteasome, the proteolytic core particle within the 26S proteasome, resulting in the accumulation of proteasome substrates and ultimately growth arrest and apoptosis of tumor cells. The development and ultimate approval of this medication by regulatory agencies has been an important step toward improving c...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Science China. Materials
سال: 2023
ISSN: ['2095-8226', '2199-4501']
DOI: https://doi.org/10.1007/s40843-023-2482-8